BriaCell Therapeutics Corp. Files S-1/A Amendment
Ticker: BCTXZ · Form: S-1/A · Filed: Apr 23, 2025 · CIK: 1610820
Sentiment: neutral
Topics: sec-filing, s-1a, biotech, public-offering
TL;DR
BriaCell files S-1/A, moving closer to public offering. Potential cash infusion ahead.
AI Summary
BriaCell Therapeutics Corp. filed an S-1/A amendment on April 23, 2025, for its registration statement. The company, formerly known as Ansell Capital Corp. until June 13, 2014, is incorporated in British Columbia and headquartered in West Vancouver, BC. This filing relates to its public offering under the Securities Act of 1933.
Why It Matters
This S-1/A filing indicates BriaCell Therapeutics is moving forward with a public offering, which could provide significant capital for its drug development programs.
Risk Assessment
Risk Level: medium — As a clinical-stage biotechnology company, BriaCell Therapeutics faces inherent risks associated with drug development, regulatory approvals, and market adoption.
Key Numbers
- 333-286670 — SEC File Number (Identifies the specific SEC registration)
- 25862239 — Film Number (Internal SEC processing number)
Key Players & Entities
- BriaCell Therapeutics Corp. (company) — Registrant
- Ansell Capital Corp. (company) — Former company name
- April 23, 2025 (date) — Filing date
- June 13, 2014 (date) — Date of name change
- Dr. William V. Williams (person) — Chief Executive Officer
- Gregory Sichenzia (person) — Legal counsel
- Avital Perlman (person) — Legal counsel
FAQ
What is the purpose of this S-1/A filing?
This is an amendment to a Form S-1 registration statement, indicating updates or revisions to BriaCell Therapeutics Corp.'s initial filing for a public offering.
When was BriaCell Therapeutics Corp. previously known by another name?
The company was formerly known as Ansell Capital Corp. until June 13, 2014.
Who is the Chief Executive Officer of BriaCell Therapeutics Corp.?
Dr. William V. Williams is the Chief Executive Officer.
What is the principal executive office address?
The principal executive offices are located at Suite 300 - 235 15th Street West Vancouver, BC V7T 2X1.
What is the company's Standard Industrial Classification code?
The company's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form S-1/A (Form S-1/A) was filed with the SEC on April 23, 2025 by Dr. William V. Williams regarding BriaCell Therapeutics Corp. (BCTXZ).